Systematic literature review of trials assessing recommended systemic treatments in hepatocellular carcinoma

Hepatic Oncology

Sarah Ronnebaum¹  Dipen Patel¹  Fernando Benavente²  Juan-David Rueda²  Abdalla Aly² 

[1] 1OPEN Health, Bethesda, MD 20814, USA;2AstraZeneca, Gaithersburg, MD 20878, USA;

关键词: BCLC stage;    ECOG performance status;    hepatocellular carcinoma;    immuno-oncology agent;    similarity assessment;    systemic treatment;   

DOI  :  10.2217/hep-2021-0003

来源: DOAJ

【 摘 要 】

Aim: To identify and evaluate the similarity of all trials assessing recommended treatments for advanced hepatocellular carcinoma. Materials & methods: Single arm and randomized trials from any phase and published any time up to February 2021 were systematically searched. Results: From 5677 records reviewed, 50 trials were included in the review, and 24 for assessed for similarity. In the first-line (1L) setting, several trials assessing sorafenib were noted for enrolling patients with more severe disease and/or performance status than other 1L trials; trials within the second-line (2L) setting were generally similar. Median survival was <2 years in all trial arms. Conclusions: Trials assessing recommended treatments are largely similar and appropriate for quantitative comparisons of several efficacy and safety outcomes.

【 授权许可】

Unknown